Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer

  • J Enzyme Inhib Med Chem. 2022 Dec;37(1):189-201. doi: 10.1080/14756366.2021.1998023.
Peter A Halim  1 Rasha A Hassan  1 Khaled O Mohamed  1 Soha O Hassanin  2 Mona G Khalil  3 Amr M Abdou  4 Eman O Osman  1
Affiliations
  • 1. Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • 2. Biochemistry Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
  • 3. Pharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.
  • 4. Department of Microbiology and Immunology, National Research Centre, Dokki, Egypt.
Abstract

Novel halogenated phenoxychalcones 2a-f and their corresponding N-acetylpyrazolines 3a-f were synthesised and evaluated for their Anticancer activities against breast Cancer cell line (MCF-7) and normal breast cell line (MCF-10a), compared with staurosporine. All compounds showed moderate to good cytotoxic activity when compared to control. Compound 2c was the most active, with IC50 = 1.52 µM and selectivity index = 15.24. Also, chalcone 2f showed significant cytotoxic activity with IC50 = 1.87 µM and selectivity index = 11.03. Compound 2c decreased both total mitogen activated protein kinase (p38α MAPK) and phosphorylated enzyme in MCF-7 cells, suggesting its ability to decrease cell proliferation and survival. It also showed the ability to induce ROS in MCF-7 treated cells. Compound 2c exhibited apoptotic behaviour in MCF-7 cells due to cell accumulation in G2/M phase and elevation in late Apoptosis 57.78-fold more than control. Docking studies showed that compounds 2c and 2f interact with p38alpha MAPK active sites.

Keywords
Halogenated chalcones; ROS; breast cancer; cell cycle profile; diaryl ether; p38 MAPK; pyrazoline.
Products